Your browser doesn't support javascript.
loading
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Motzer, Robert J; Russo, Paul; Grünwald, Viktor; Tomita, Yoshihiko; Zurawski, Bogdan; Parikh, Omi; Buti, Sebastiano; Barthélémy, Philippe; Goh, Jeffrey C; Ye, Dingwei; Lingua, Alejo; Lattouf, Jean-Baptiste; Albigès, Laurence; George, Saby; Shuch, Brian; Sosman, Jeffrey; Staehler, Michael; Vázquez Estévez, Sergio; Simsek, Burcin; Spiridigliozzi, Julia; Chudnovsky, Aleksander; Bex, Axel.
Affiliation
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA. motzerr@mskcc.org.
  • Russo P; Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Grünwald V; Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany.
  • Tomita Y; Department of Urology and Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Zurawski B; Department of Outpatient Chemotherapy, Prof. Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Poland.
  • Parikh O; Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust, Preston, UK.
  • Buti S; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Barthélémy P; Medical Oncology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Goh JC; ICON Research, South Brisbane, and Queensland University of Technology, Brisbane, QLD, Australia.
  • Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Lingua A; Instituto Médico Río Cuarto, Río Cuarto, Argentina.
  • Lattouf JB; Department of Surgery-Urology, CHUM-Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
  • Albigès L; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
  • George S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Shuch B; University of California, Los Angeles, Los Angeles, CA, USA.
  • Sosman J; Northwestern University Medical Center, Chicago, IL, USA.
  • Staehler M; Interdisciplinary Centre on Renal Tumors, University of Munich, Munich, Germany.
  • Vázquez Estévez S; Hospital Universitario Lucus Augusti (HULA), EOXI de Lugo, Cervo e Monforte, Lugo, Spain.
  • Simsek B; Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.
  • Spiridigliozzi J; Department of Oncology Late Clinical Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • Chudnovsky A; Department of Oncology, Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • Bex A; Takeda Pharmaceuticals, Boston, MA, USA.
Target Oncol ; 18(5): 639-641, 2023 09.
Article in En | MEDLINE | ID: mdl-37659025
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Target Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Francia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Target Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Francia